SCHEMBL7097864

SCHEMBL7097864

CCc1nc2cc(C(F)(F)F)ccc2n1-c1c[c]ccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 6/20 0.41
BMI1 P35226 4/20 0.39
BRD9 Q9H8M2 1/20 0.39
CNR1 P21554 1/20 0.39
PDE2A O00408 2/20 0.36
PDE10A Q9Y233 2/20 0.36
CACNA1D Q01668 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP1A2 P05177 2/20 0.35
HTR3E A5X5Y0 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HTR3B O95264 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
HTR1A P08908 1/20 0.35
CYP2D6 P10635 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35
HTR1D P28221 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27600130 0.84 PDE10A (0.40) PDE10ACYP1A2KDM4E
SCHEMBL27600071 0.82 PDE10A (0.40) PDE10AMEN1KMT2ACYP1A2KDM4E
SCHEMBL27599854 0.82 ALDH1A1 (0.51) CNR2PDE10ACYP1A2KDM4E
SCHEMBL28754629 0.82 PDE10A (0.40) PDE10ACYP1A2TP53TSHRHSD17B10
SCHEMBL7098437 0.81 HSD17B10 (0.41) MEN1KMT2ATP53HSD17B10
SCHEMBL7097335 0.81 NR1H2 (0.37) CNR2BMI1BRD9CNR1PDE10A
SCHEMBL27618382 0.80 PDE10A (0.38) PDE10ACYP1A2KDM4E
SCHEMBL27599860 0.80 PDE10A (0.39) PDE10ACYP1A2HSD17B10
SCHEMBL27600144 0.80 MAPK1 (0.46) BMI1PDE10AMEN1KMT2ACYP1A2
SCHEMBL7098797 0.78 ESR1 (0.34) PDE10ACYP1A2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236260-A1 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases SHIMOJO MASATO 2003-12-25 US disclosed
EP-1326606-A2 EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS PFIZER PHARMACEUTICALS INC. (JP) 2003-07-16 EP disclosed
EP-1326864-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2003-07-16 EP disclosed
WO-2002032422-A2 EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO disclosed
WO-2002032900-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236260-A1 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PTGER4, PTGER1, IL6 CNR2 165/4885BMI1 4627/4885BRD9 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.